openPR Logo
Press release

Proteros and Hutchison MediPharma enter into long-term research collaboration agreement

05-17-2011 08:45 PM CET | Science & Education

Press release from: Proteros biostructures GmbH

Martinsried, Germany, May 17, 2011. Proteros Biostructures GmbH (“Proteros”) announced today that they entered into a substantial research collaboration agreement with Hutchison MediPharma Limited (“HMP”), whereby Proteros will support HMP’s drug discovery process throughout 2011 and beyond.

Under the agreement Proteros initially will provide high quality crystallography services on certain projects to support HMP’s drug discovery projects. HMP is focused on the areas of oncology and autoimmune diseases. Proteros will support HMP’s discovery research with Protein-Ligand-structure analysis throughout 2011 and beyond with selected compounds from HMP. This collaboration will significantly accelerate HMP’s drug discovery process, particularly in medicinal chemistry.

Cony D’Cruz, Chief Business Officer and President Proteros US, Inc. stated, “We are very pleased to be selected by Hutchison MediPharma to work with it on its multitude of exciting targets and we believe that our in-depth structural biology expertise is particularly suited to accelerate its efforts in its target areas.”

About Proteros:

Proteros is a privately held company that provides services and proprietary technologies to support integrated drug discovery within life sciences. The company accelerates and improves protein structure analysis, kinetic and thermodynamic compound-target interaction studies and structure-guided drug discovery with its expertise, industrialized processes and unique technologies for crystallography, screening, and fragment-based lead generation. Proteros currently provides services for more than 80 pharmaceutical and biotechnology clients in Europe, North America and Asia.

About Hutchison MediPharma:

Hutchison MediPharma is a novel pharmaceutical research & development company focused on discovering, developing and commercializing innovative therapeutics in oncology and autoimmune diseases. With a team of over 200 scientists, its pipeline includes novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and Greater China.

Contact
Proteros biostructures GmbH
Kurt Herrenknecht, Ph.D.
Am Klopferspitz 19
82152 Martinsried
Germany
Phone: +49 89 7007 61 0
E-Mail: business@proteros.com
Internet: www.proteros.com

Hutchison MediPharma Limited
Building 4, 720 Cailun Road
Zhangjiang Hi-Tech Park
Shanghai, 201203
China
Phone: +86 21 5079 0088
E-Mail: BD@hmplglobal.com
Internet: www.hmplglobal.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Proteros and Hutchison MediPharma enter into long-term research collaboration agreement here

News-ID: 175361 • Views: 1488

More Releases from Proteros biostructures GmbH

PROTEROS ANNOUNCES SUCCESSFUL CLOSE OF FINANCING ROUND
Largest-ever Financing allows for Expansion of Drug Discovery Capabilities MARTINSRIED, GERMANY (August 6th, 2012) – Proteros biostructures GmbH (‘Proteros’) announced today that it had successfully closed a financing round of five million Euros to fund the continued expansion and growth of the company. The financing round was led by BayBG, a key equity investor for Proteros. The financing round is the third and largest investment into the firm since the inception
Proteros and Eisai Co., Ltd enter into Integrated Lead Discovery Collaboration
Martinsried (Germany), April 16, 2012. Proteros biostructures GmbH today announced that the company has entered into a research collaboration with Eisai Co., Ltd (Japan) to identify small molecule inhibitors against a target selected by Eisai in the field of immunology. Under the agreement Proteros will deliver a novel lead compound applying its integrated lead discovery platform that includes X-Ray structural biology, biophysical screening and profiling, novel fragment libraries and medicinal chemistry
Proteros announces the appointment of Dr. Klaus Hinterding as Chief Scientific O …
Martinsried, Germany, February 9, 2012. Proteros biostructures GmbH (Proteros) announced today that Dr. Klaus Hinterding, formerly at Hoffmann-La Roche Ltd. (Roche), has joined the company as Chief Scientific Officer and member of the management board. Dr. Hinterding brings to Proteros considerable pharmaceutical industry experience that spans early research through to clinical development in various therapeutic areas. At Novartis, his research contributed to the understanding of the mode-of-action of GilenyaTM, licensed for
Janssen Pharmaceutica NV and Proteros expand relationship and enter into Global …
Martinsried Jan 09, 2012. Janssen Research & Development, a division of Janssen Pharmaceutica NV (“Janssen”) and Proteros biostructures GmbH (“Proteros”) today announced they have entered into a long-term global service agreement granting Janssen privileged access to Proteros portfolio of discovery technologies and services. Under the agreement Janssen will have broad access to Proteros’ drug discovery technologies, including structural biology, biophysical screening and profiling service, novel fragment libraries, medicinal chemistry expertise and

All 5 Releases


More Releases for HMP

Global Enterprise Contract Management Solutions Market 2019 Survey In New Resear …
“Enterprise Contract Management Solution” is a means of streamlining and improving the way contracts are stored and reviewed throughout the organization. Enterprise Contract Management Solutions Market report provides a composite view of the sub-market combined with a comprehensive industry domain and provides the right method of accounting elements such as norms, regulations, and cultures to establish a compensation strategy appropriate to the market plan. The Global Enterprise Contract Management Solutions
Trend Expected to Guide Heterogeneous Mobile Processing and Computing Market Dur …
Heterogeneous mobile processing (HMP) and computing utilizes various components such as graphical processor unit and central processing unit together on a same silicon chip to provide power efficiency and improved performance. HMP improves the 3D graphic capabilities. It is able to perform mathematical intensive calculation on large data sets. HMP and computing combines the benefit of different components such as graphical processing unit (GPU), central processing unit (CPU) and field-programmable
Insightful Forecast on Expansion of Global Heterogeneous Mobile Processing and C …
Heterogeneous mobile processing (HMP) and computing utilizes various components such as graphical processor unit and central processing unit together on a same silicon chip to provide power efficiency and improved performance. HMP improves the 3D graphic capabilities. It is able to perform mathematical intensive calculation on large data sets. HMP and computing combines the benefit of different components such as graphical processing unit (GPU), central processing unit (CPU) and field-programmable
Heterogeneous Mobile Processing and Computing Market to Rear Excessive Growth Du …
Heterogeneous mobile processing (HMP) and computing utilizes various components such as graphical processor unit and central processing unit together on a same silicon chip to provide power efficiency and improved performance. HMP improves the 3D graphic capabilities. It is able to perform mathematical intensive calculation on large data sets. HMP and computing combines the benefit of different components such as graphical processing unit (GPU), central processing unit (CPU) and field-programmable
Heterogeneous Mobile Processing and Computing Market Size, Analysis, and Forecas …
Heterogeneous mobile processing (HMP) and computing utilizes various components such as graphical processor unit and central processing unit together on a same silicon chip to provide power efficiency and improved performance. HMP improves the 3D graphic capabilities. It is able to perform mathematical intensive calculation on large data sets. HMP and computing combines the benefit of different components such as graphical processing unit (GPU), central processing unit (CPU) and field-programmable
Heterogeneous Mobile Processing and Computing Market 2014-2020 Shares, Trend and …
Heterogeneous mobile processing (HMP) and computing utilizes various components such as graphical processor unit and central processing unit together on a same silicon chip to provide power efficiency and improved performance. HMP improves the 3D graphic capabilities. It is able to perform mathematical intensive calculation on large data sets. HMP and computing combines the benefit of different components such as graphical processing unit (GPU), central processing unit (CPU) and field-programmable